结外滤泡树突细胞肉瘤的临床病理学特征
本研究收集7例结外滤泡树突细胞肉瘤(FDCS)标本,进行HE染色、免疫组化、BRAF V600E实时PCR检测及EBER原位杂交。结果显示CD21、CD23、CD35等一线抗体及D2-40、CXCL13、EGFR等二线抗体有助于诊断和鉴别诊断,5例PD-L1阳性且高级别表达高于低级别,7例均未检出BRAF V600E突变,仅1例鼻咽部FDCS EBER阳性。
要点
- 一线抗体CD21、CD23、CD35联合二线抗体D2-40、CXCL13、EGFR有助于FDCS诊断和鉴别诊断。
- 7例中5例表达PD-L1,高级别FDCS表达强度和阳性细胞数高于低级别FDCS。
- 7例均未检出BRAF V600E基因突变,仅1例鼻咽部FDCS EBER原位杂交阳性。
核心结论
- FDCS是一种易复发和转移的罕见恶性肿瘤。
- 一线抗体CD21、CD23、CD35联合二线抗体D2-40、CXCL13、EGFR的应用有助于其诊断和鉴别诊断。
- PD-L1的高表达提示部分患者可能会从免疫治疗中获益。
研究设计与样本
- 收集7例结外FDCS患者标本,对肿瘤组织进行HE染色和免疫组化染色。
- 采用实时PCR法检测7例肿瘤组织中BRAF V600E基因突变情况,并对4例肿瘤组织进行EBER原位杂交。
主要发现
- 7例中男5例、女2例,中位年龄55岁;低级别FDCS 4例,高级别FDCS 3例。
- 肿瘤位于纵隔2例,鼻咽部、肾脏、肺、直肠和肝脏各1例。
- 免疫组化显示CD21、CD23、CD35、D2-40、CXCL13、EGFR呈弥漫或灶状阳性,S-100、CD68、HMB45、SMA、Desmin、CD117、Dog-1、CD34、CD30、EMA、CK均阴性。
- 7例中5例表达PD-L1,高级别FDCS表达强度和阳性细胞数高于低级别FDCS。
- 免疫组化BRAF V600E阳性2例且均为低级别FDCS,但PCR检测7例标本均未见BRAF V600E基因突变;EBER原位杂交仅1例鼻咽部FDCS阳性。
关键数值与推荐
- 一线抗体为CD21、CD23、CD35,二线抗体为D2-40、CXCL13、EGFR。
- 随访7~43个月,4例死亡,1例生存(直肠转移),2例失访。
临床怎么用
- 作者认为一线抗体CD21、CD23、CD35联合二线抗体D2-40、CXCL13、EGFR的应用有助于FDCS的诊断和鉴别诊断。
- 作者认为PD-L1的高表达提示部分FDCS患者可能会从免疫治疗中获益。
局限性
- 随访7~43个月,4例死亡,1例生存,2例失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical pathologic characteristics of extranodal follicular dendritic cell sarcoma (FDCS). Methods: We collected 7 cases of extranodal FDCS, HE staining, immunohistochemical study were performed. The V600E mutation of BRAF in 7 cases were detected by real-time PCR and EBER in situ hybridization was performed on 4 cases. Results: Among the 7 cases of FDCS, 5 cases were male and 2 cases were female, the median age was 55 years old, including 4 cases of low-grade FDCS and 3 cases of high-grade FDCS. The tumor location of 2 cases was in mediastinum, the tumor locations of others were in nasopharynx, kidney, lung, rectum and liver, respectively. The results of immunohistochemistry showed that, the tumor cells were diffusely or focally positive for CD21, CD23, CD35, D2-40, EGFR and CXCL13, but negative for S-100, CD68, HMB45, SMA, Desmin, CD117, Dog-1, CD34, CD30, EMA and CK.Five cases were positive for PD-L1 and the its expression in high-grade FDCS were higher than that in low-grade FDCS.Two cases of low-grade FDCS were positive for BRAF V600E, but the BRAF V600E mutation weren't detected in all of 7 cases. The result of EBER in-situ hybridization showed that only the nasopharynx FDCS was positive.The follow-up information of 5 patients were available (7~43 months), 4 patients died and 1 still alive with rectum metastasis. Conclusions: FDCS is a rare malignant disease with relapse and metastatic tendency. The combined applications of the first-line antibodies including CD21, CD23, CD35 and second-line antibodies including D2-40, CXCL13, EGFR are helpful for its diagnosis and differential diagnosis. The high expression of PD-L1 implicates the potential benefit of FDCS patients acquired from immunotherapy. 目的: 研究结外滤泡树突细胞肉瘤(FDCS)的临床病理学特点。 方法: 收集7例结外FDCS患者标本,对肿瘤组织进行HE染色和免疫组化染色。采用PCR法检测7例肿瘤组织中BRAF V600E基因的突变情况,并对4例肿瘤组织进行EBER原位杂交。 结果: 7例患者中,男5例,女2例;中位年龄55岁。发生于鼻咽部、肾脏、肺、直肠和肝脏各1例,纵隔2例。低级别FDCS 4例,高级别FDCS 3例。免疫组化染色显示,CD21、CD23、CD35、D2-40、CXCL13、EGFR呈弥漫或灶状阳性,S-100、CD68、HMB45、SMA、Desmin、CD117、Dog-1、CD34、CD30、EMA、CK均阴性。7例FDCS中,有5例表达PD-L1,且高级别FDCS表达强度和阳性细胞数高于低级别FDCS。免疫组化染色显示,BRAF V600E阳性表达2例,且均为低级别FDCS。PCR检测结果显示,7例标本均未见BRAF V600E基因突变。EBER原位杂交显示,1例鼻咽部FDCS患者阳性。随访7~43个月,4例死亡,1例生存,2例失访。 结论: FDCS是一种易复发和转移的罕见恶性肿瘤,一线抗体CD21、CD23、CD35联合二线抗体D2-40、CXCL13、EGFR的应用有助于其诊断和鉴别诊断。PD-L1的高表达提示部分患者可能会从免疫治疗中获益。.
引用
- Cui LF, Zhang JX, Li Z, et al. [Clinical pathologic characteristics of extranodal follicular dendritic cell sarcoma]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 30917459. doi:10.3760/cma.j.issn.0253-3766.2019.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。